Pediatric Diabetes· 2015Q1
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
- 42citations
- Q1SCImago
- 2015year
Short summary
Metformin and other non-insulin therapies may help manage insulin resistance and improve glycemic control in youth with type 1 diabetes (T1DM).
AI-generated from the title and abstract; the full text is not read.
Key points
- Insulin resistance is increasingly recognized in youth with type 1 diabetes (T1DM).
- Management of T1DM in youth should address glycemic control, insulin resistance, and cardiovascular risk factors.
- Metformin is discussed as an adjunctive therapy to improve glycemic control and mitigate insulin resistance in T1DM.
- Other new pharmacologic agents for T1DM management are also reviewed.
AI-generated from the title and abstract; the full text is not read.
Abstract
Type 1 diabetes mellitus (T1DM) in youth is a challenging chronic medical condition. Its management should address not only the glycemic control but also insulin resistance and cardiovascular disease risk factors which are increasingly recognized to be present in youth with TID. Current knowledge on the mechanisms of insulin resistance in T1DM is reviewed. The use of adjunctive therapies that are beneficial to achieve adequate glycemic control while mitigating the effects of insulin resistance are discussed with a focus on metformin therapy and an overview of other new pharmacologic agents.
The authors' abstract, as published at the source. Pediatric Diabetes, 2015 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine